Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans.
The majority of patients who develop bronchiolitis obliterans, after lung transplantation, die within 2-3 yrs after onset since treatment with conventional immunosuppression is typically ineffective. A case/control study was conducted in lung transplant recipients with biopsy-documented bronchiolitis obliterans to determine whether aerosol cyclosporin use contributed to increased survival. The cases comprised 39 transplant recipients who received open-label aerosol cyclosporin treatment in addition to conventional immunosuppression. The controls were transplant recipients treated with conventional immunosuppression alone. There were 51 controls from the University of Pittsburgh Medical Center and 100 from a large multicentric database (Novartis Lung Transplant Database). Forced expiratory volume in one second expressed as a percentage of the predicted value was an independent predictor of survival in all patients with bronchiolitis obliterans. Cox proportional-hazards analysis revealed a survival advantage for aerosol cyclosporin cases compared to the Pittsburgh control group. A survival advantage was also seen when comparing study cases to multicentric controls. Aerosol cyclosporin, given with conventional immunosuppression to lung transplant recipients with bronchiolitis obliterans, provides a survival advantage over conventional therapy alone.
Iacono
A T
AT
Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA. iaconoat@msx.upmc.edu
Corcoran
T E
TE
Griffith
B P
BP
Grgurich
W F
WF
Smith
D A
DA
Zeevi
A
A
Smaldone
G C
GC
McCurry
K R
KR
Johnson
B A
BA
Dauber
J H
JH
D000280:Administration, Inhalation; D000328:Adult; D000336:Aerosols; D001989:Bronchiolitis Obliterans / Q000188:drug therapy* / Q000401:mortality; D016022:Case-Control Studies; D016572:Cyclosporine / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016040:Lung Transplantation / Q000401:mortality; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy* / Q000401:mortality; D016016:Proportional Hazards Models; D016019:Survival Analysis
D000336:Aerosols; D007166:Immunosuppressive Agents; D016572:Cyclosporine